insights_auto
Why is BH3 up 2,59%?
Dive Deeperchevron_right
BH3:FRA
PTC Therapeutics, Inc.
€55,54
arrow_upward
+2,59%(+1,40) 1D
20 Okt., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€53,56
High
€55,54
Low
€53,56
Mkt. cap
5,25 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
€77,02
52-wk low
€51,64
No. of employees
991
Open
€53,56
High
€55,54
Low
€53,56
Mkt. cap
5,25 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
€77,02
52-wk low
€51,64
No. of employees
991
News stories
From web sources and news partners
ad-hoc-news.de
·
5 uur gelede
PTC Therapeutics schedules October 29 results as stock trades below its high
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded01 Jan. 1998
HeadquartersWarren, New Jersey, Verenigde State van Amerika
Sector-
Websiteptcbio.com